Prenetics Global Valuation

Is PRE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PRE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PRE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PRE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRE?

Key metric: As PRE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PRE. This is calculated by dividing PRE's market cap by their current revenue.
What is PRE's PS Ratio?
PS Ratio	2.4x
Sales	US$22.66m
Market Cap	US$54.00m

PRE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PRE's PS Ratio compare to its peers?

The above table shows the PS ratio for PRE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.3x
ENZ Enzo Biochem	1.6x	n/a	US$50.7m
ME 23andMe Holding	0.4x	n/a	US$80.4m
CCEL Cryo-Cell International	2.1x	1.0%	US$67.3m
CDIX Cardiff Lexington	13.1x	n/a	US$98.9m
PRE Prenetics Global	2.4x	93.6%	US$54.0m

Price-To-Sales vs Peers: PRE is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (4.3x).

Price to Sales Ratio vs Industry

How does PRE's PS Ratio compare vs other companies in the US Healthcare Industry?

30 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$79.11b
CVS CVS Health	0.2x	4.6%	US$73.00b
COR Cencora	0.2x	6.4%	US$48.03b
CNC Centene	0.2x	5.5%	US$30.48b

30 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PRE is expensive based on its Price-To-Sales Ratio (2.4x) compared to the US Healthcare industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is PRE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.4x
Fair PS Ratio	35.1x

Price-To-Sales vs Fair Ratio: PRE is good value based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (35.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

18.8%

27.5%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

0.5%

-15.7%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

16.2%

99.5%